Revvity reported third‑quarter diagnostics revenue growth driven by its newborn screening business and immunodiagnostics, citing CE marking for an updated lysosomal storage disease panel and a Genomics England partnership that supports large‑scale newborn DNA workflows. The company expects newborn screening momentum to continue and views population‑scale assays, including a high‑throughput type 1 diabetes test co‑developed with Sanofi, as growth levers. Revvity posted modest overall revenue gains and raised EPS guidance while noting geographic headwinds in China. Management pointed to newborn screening as a durable, high‑value segment that can underpin further diagnostics expansion. Investors will watch regulatory clearances for new assays and commercialization execution in population screening programs to validate the growth thesis.